The Online Investor

Slideshow Stock Splits

By The Online Investor Staff, updated Sun., Aug. 19, 11:47 AM

Slide #2. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) 1 for 8 Reverse Split

Announced: 7/27/2018
Stock Split: 1 for 8
Record Date: 7/27/2018
Pay Date: 7/30/2018
IDRA Optionable?: Yes

Idera Pharmaceuticals is a biopharmaceutical company. Co. utilizes two proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor (TLR); and its nucleic acid. Co.'s TLR drug candidates are: IMO-2125, an indication for Anti-PD1 Refractory Metastatic Melanoma and Refractory Solid Tumors; and IMO-8400, an indication for Dermatomyositis. Co.'s Nucleic Acid Chemistry research programs comprised of: IDRA-008, for treatment of Familial Chylomicronemia Syndrome and Familial Partial Lipodystrophy; Nucleic Acid Chemistry Compound, an indication for renal disease; and IMO-9200, an indication for non-malignant Gastrointestinal Disorders.

IDRA SEC Filing Email Alerts Service

IDRA Detailed Information Page & Split History »

Company Name: 
Idera Pharmaceuticals Inc
Website: 
www.iderapharma.com
Sector: 
Biotechnology
Number of ETFs Holding IDRA: 
10
Total Market Value Held by ETFs: 
$6.08M
Total Market Capitalization: 
$249.00M
% of Market Cap. Held by ETFs: 
2.44%

Open the IDRA Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
91st percentile
(ranked higher than approx. 91% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Stock Splits Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2018, All Rights Reserved Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.